Targeting the Genomic Drivers of Cancer
Kinnate is driven by the urgency of cancer patients who need more effective therapies. Our Kinnate Discovery Engine, which starts with the identification of an unmet need among validated oncogenic drivers, utilizes our deep expertise in medicinal chemistry and tailored ecosystems of partners to advance the development of targeted oncology therapy candidates.
Our lead programs include candidates in development for cancers that are driven by specific oncogenic alterations in kinase genes including BRAF Class II and Class III, NRAS, and FGFR2 and FGFR3. To help move our programs forward, Kinnate has brought together a management team of precision oncology leaders and scientific advisors who publish widely cited research on topics relevant to the study and treatment of cancer and lead clinical units at experienced precision medicine centers in the United States.
Kinnate Discovery Engine
“Kinnate has assembled an experienced team of precision oncology experts who are focused on the discovery and development of precision medicines for difficult-to-treat genomically defined cancers.”
– Keith T. Flaherty, MD, Kinnate Board and SAB Member
Unmet Need in Targeted Cancer Therapeutics
In the context of cancer treatment, precision medicine represents the genomic sequencing and analysis of a patient’s tumor combined with the development and administration of therapies that are designed to target the oncogenic driver to which the cancer is addicted. It has been shown that people with tumors driven by oncogenic kinases may experience rapid and measurable tumor shrinkage when treated with targeted kinase inhibitors. Furthermore, while therapeutic benefit can often be significant and clinically meaningful, tolerability is frequently improved when compared to conventional cancer treatments such as chemotherapies.
However, despite the advancement of precision medicine in oncology, there remains a significant unmet need for the majority of cancer patients for whom no genomically targeted therapies exist or for which a resistance to targeted treatments has emerged. It is estimated that only 2% to 3% of people with advanced or metastatic cancer will have durable responses to currently available targeted therapeutics.
Currently, it is estimated that just 10% of all patients with advanced or metastatic cancer are eligible for targeted therapeutics – in which a defined genomic driver is matched with a currently approved targeted therapy. Of those people, up to 50% (the responders) will respond to the therapy, while the remainder (the non-responders) gain no clinical benefit due to intrinsic resistance. Furthermore, among the responders, the majority (conservatively estimated at 50% to 80%) will eventually develop acquired resistance, lose their beneficial response to therapy, and experience disease progression despite continued treatment with the targeted therapy.
At Kinnate, we are focused on expanding the reach of targeted oncology therapeutics and developing products that address areas of significant unmet need. We believe our Kinnate Discovery Engine will enable us to more quickly identify viable targets and successfully bring those candidates into the clinic. Based on our progress to date, we believe that this biomarker-driven drug-development strategy paired with continual translational research collaborations and a global footprint can potentially lead to new targeted therapy products that support meaningfully better outcomes for people with cancer.
“There are clear drivers of disease and resistance mutations that will cause current therapies to fail. The Kinnate portfolio addresses these challenges and will potentially contribute meaningful new medicines to patient populations that would benefit from them.”
– Ryan Corcoran, MD, PhD, Kinnate SAB Member